Where Nevro Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analyst ratings for Nevro (NYSE:NVRO) have remained neutral over the last quarter, with all four analysts giving indifferent ratings. The 12-month price targets have been adjusted downwards, with an average target now at $18.00, down from a previous average of $21.00. Analysts from Citigroup, Wells Fargo, Baird, and RBC Capital have all lowered their price targets for NVRO, reflecting changing market dynamics and company performance. Nevro, a medical device company specializing in the HFX spinal cord stimulation platform, has shown a positive revenue trend with a growth rate of 2.05% as of December 31, 2023, but lags behind industry peers. The company's financial performance is strong, with exceptional net margin and ROE exceeding industry averages, and a healthy debt-to-equity ratio.
April 03, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have maintained a neutral stance on NVRO, with recent adjustments to price targets reflecting a cautious outlook. Despite a positive revenue trend, NVRO's performance is seen as lagging behind industry peers. However, the company's strong financial metrics, such as net margin and ROE, suggest a solid foundation.
The neutral ratings and downward adjustment of price targets by analysts indicate a cautious but not pessimistic view on NVRO's short-term stock performance. The company's strong financial health, as evidenced by its net margin and ROE, provides a solid foundation, potentially mitigating negative impacts from the market's cautious outlook. The relevance of this news to NVRO is direct, given it pertains specifically to analyst ratings and financial performance of the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100